Skip Navigation LinksHome > March 2013 - Volume 23 - Issue 3 > Does Extensive Upper Abdomen Surgery During Primary Cytoredu...
International Journal of Gynecological Cancer:
doi: 10.1097/IGC.0b013e3182842fc4
Ovarian Cancer

Does Extensive Upper Abdomen Surgery During Primary Cytoreduction Impact on Long-term Quality of Life?

Angioli, Roberto MD*; Plotti, Francesco MD*; Aloisi, Alessia MD*; Capriglione, Stella MD*; Terranova, Corrado MD*; Ricciardi, Roberto MD*; Montera, Roberto MD*; Zullo, Marzio Angelo MD*; Rasi, Virginia MD; Benedetti-Panici, Pierluigi MD

Collapse Box

Abstract

Objectives: The objective of this study was to evaluate the feasibility in terms of safety and quality of life in a sample of Italian patients affected by advanced ovarian cancer and submitted to either extensive upper abdomen or standard surgery, through validated questionnaires.

Methods: From January 2006 to November 2011, a prospective, observational study was conducted to compare quality of life in patients affected by advanced ovarian cancer and submitted to primary cytoreduction in the Division of Gynecology of the University Campus Bio-Medico of Rome. After surgery patients were stratified into 2 groups (group A: standard surgery or group B: extensive upper abdomen surgery). All patients were submitted to standard chemotherapy. At completion of treatment, during the first follow-up visit, all eligible patients were asked to fill in Quality of Life Questionnaire-C30 (QLQ-C30) (version 3.0) and European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire-OV28 (QLQ-OV28) questionnaires.

Results: Eighty-nine patients were enrolled into our study. Nine were excluded, so finally 80 patients were considered in this study. Group A included 40 patients and underwent standard surgery (pelvic surgery); group B, included 40 patients and underwent extensive upper abdomen surgery. There were no statistical differences in terms of major surgical complication rates (15% vs 10%). We registered same times of beginning of chemotherapy (median, 19 vs 21 days) and no severe related toxicities. Quality-of-life scores of both questionnaires were comparable between groups, with the exception of Global Health Status in QLC-30.

Conclusions: Upper abdomen surgery is a feasible and safe therapeutic option. Patients present same times of beginning of chemotherapy without an increase in chemorelated toxicities and experience the same general quality of life.

Copyright © 2013 by IGCS and ESGO

Login

Article Tools

Share

Search for Similar Articles
You may search for similar articles that contain these same keywords or you may modify the keyword list to augment your search.

Connect With Us

Twitter
twitter.com/IJGConline

For additional oncology content, visit LWW Oncology Journals on Facebook.